The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
Keep in mind: There's no perfect schedule
5 benign features (background brown pigmentation, parallel lines, circular lines, overlapping vessels, and structureless black pigmentation) and 5 malignant features (irregular network, irregular dots and globules, blue-white veil, atypical vessels, and reticular depigmentation)3, 4, 5, 6
Ambalaj aldktan sonra, retici nerisine gre mmknse ksa srede tketilmelidir
Skipping the heat tools